enGene Holdings Inc. Common Stock (ENGN)
$
3.84
-0.12 (-3.13%)
Key metrics
Financial statements
Free cash flow per share
-1.3207
Market cap
216.5 Million
Price to sales ratio
0
Debt to equity
0.1006
Current ratio
17.1609
Income quality
0.9647
Average inventory
0
ROE
-0.2773
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company focused on developing genetic medicines designed to deliver therapeutics to mucosal tissues and other organs. The company reported depreciation and amortization expenses of $0.00 reflecting the wear and tear of its assets. Its lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy aimed at treating non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis) who do not respond to Bacillus Calmette-Guérin treatment. The income before tax ratio is 0.00 illustrating the pre-tax margin of the company. Further, the diluted EPS is $0.15 which accounts for potential share dilution and provides insight into the earnings available for shareholders. The gross profit ratio is 0.00 a key indicator that reflects the efficiency of the company's production and sales operations. Additionally, the company incurred an income tax expense of -$19,000.00 indicating its tax obligations and financial responsibilities within its operational framework. Founded in 2023 and based in Saint-Laurent, Canada, enGene is positioned within the dynamic biotechnology landscape. As an emerging player in the market, the stock is affordable at $3.96 making it suitable for budget-conscious investors looking to enter the biotechnology field. The stock has a low average trading volume of 57,934.00 which indicates lower market activity and may appeal to those seeking less volatility. With a market capitalization of $196,112,064.00 the company is classified as a small-cap player within the industry. As a key participant in the Biotechnology industry, enGene contributes significantly to the overall market landscape, fostering advancements in genetic therapies. It belongs to the Healthcare sector, actively driving innovation and growth in a rapidly evolving market. As such, enGene Holdings Inc. stands out as a company that not only provides promising therapeutic solutions but also represents a compelling opportunity for investors interested in the future of biotechnology.
Is enGene Holdings Inc. Common Stock (ENGN) a good investment?
Investing in enGene Holdings Inc. Common Stock (ENGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is enGene Holdings Inc. Common Stock (ENGN)'s stock forecast?
Analysts predict enGene Holdings Inc. Common Stock stock to fluctuate between $2.65 (low) and $11 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is enGene Holdings Inc. Common Stock's market capitalization?
As of 2025-05-30, enGene Holdings Inc. Common Stock's market cap is $196,112,064, based on 51,070,850 outstanding shares.
How does enGene Holdings Inc. Common Stock compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, enGene Holdings Inc. Common Stock has a Lower Market-Cap, indicating a difference in performance.
Does enGene Holdings Inc. Common Stock pay dividends?
enGene Holdings Inc. Common Stock pays dividends. The current dividend yield is 2.85%, with a payout of $0.13 per share.
How can I buy enGene Holdings Inc. Common Stock (ENGN) stock?
To buy enGene Holdings Inc. Common Stock (ENGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENGN. Place an order (Market, Limit, etc.).
What is the best time to invest in enGene Holdings Inc. Common Stock?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did enGene Holdings Inc. Common Stock perform in the last earnings report?
Revenue: $0 | EPS: $0.15 | Growth: -103.54%.
Where can I find enGene Holdings Inc. Common Stock's investor relations reports?
Visit https://www.engene.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for enGene Holdings Inc. Common Stock?
You can explore historical data from here
What is the all-time high and low for enGene Holdings Inc. Common Stock stock?
All-time high: $43 (2023-11-01) | All-time low: $2.65 (2025-05-13).
What are the key trends affecting enGene Holdings Inc. Common Stock stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
2 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. A.
businesswire.com
3 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to.
businesswire.com
a month ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,.
businesswire.com
2 months ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price.
businesswire.com
2 months ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene e.
businesswire.com
3 months ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. “With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026,” said Ron Cooper, Chief Executive Officer o.
seekingalpha.com
3 months ago
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.
zacks.com
3 months ago
NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024.
zacks.com
3 months ago
GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024.
businesswire.com
4 months ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to.
See all news
